Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

to moderate adverse events so that the prescribed dose can be maintained whenever possible. However, in some cases, either a dose reduction or interruption of treatment with Gleevec may be necessary

Gleevec tablets should be taken with food and a large glass of water to minimize GI irritation. Gleevec tablets should not be taken with grapefruit juice

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "will," "planned," or similar expressions, or by express or implied discussions regarding potential future regulatory submissions, new indications or new labeling for Gleevec, the long-term impact of a patient's use of Gleevec or potential future sales of Gleevec. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that additional regulatory submissions will be made in any particular jurisdictions, or that Gleevec will be approved for any additional indications or labeling in any market. Nor can there be guarantee regarding the long-term impact of a patient's use of Gleevec. Neither can there be any guarantee regarding potential future sales of Gleevec. In particular, management's expectations regarding Gleevec could be affected by, among other things, unexpected clinical trial results, including additional analysis of Gleevec clinical data, and new clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and other risks and factors referred to in the Company's current Form 20-F on file with the US Securities and Exchange Commission. Should one or
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/29/2014)... 29, 2014  The Healthcare Analytics Summit 2014 ... Salt Lake City , Sept. 24-25 ... respected healthcare organizations in the U.S. and beyond.  HAS ... industry conference devoted to providing immersive learning experiences on ... of both accountable care initiatives and population health ...
(Date:7/29/2014)... IRVING, Texas , July 29, 2014 /PRNewswire/ ... three new web-based applications with breakthrough interactive features ... and workflows for members of Children,s Hospital Association.  ... under the Novation Optimize Solutions umbrella – Value ... of how Novation helps organizations address the most ...
(Date:7/29/2014)... DIEGO , July 29, 2014   ... Nancy Thornberry to its board of ... franchise head, Diabetes and Endocrinology for Merck & ... strategy and overall pipeline management in diabetes, osteoporosis, ... initiated and co-led the program that resulted in ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Research, TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- ... that,(1) demonstrate that Azixa(TM) (MPC-6827) is effective in ... (2) reveal a,mechanism by which MPC-6827 exerts its ... by cellular proteins known to be involved,in cancer ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... improvement measures in eight of the 10 hospitals in ... have found a way to reduce kidney injury in ... 7-15 percent of these patients who undergo a coronary ... which can result in death or rapid decline in ... a study published in the July issue of ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... Avenidas is always looking for ways to ... non-profit agency is doing just that with the Third Annual ... event gives seniors the opportunity to learn about how they ... a variety of fun activities, including a Tai Chi demonstration, ... In addition, there will be food tastings, courtesy of Lyfe ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... - Researchers from the Boston University School of Medicine ... a $3.5 million grant from the National Institute on ... treat, and retain" paradigm in Eastern Europe among HIV-infected ... narcology (addiction) care. The project will be known as ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... Mozes HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... people to develop cancer, new British research says. Among ... leukemia or melanoma appears to go up about 16 percent ... "Taller women in our study had increased risk of a ...
... , THURSDAY, July 21 (HealthDay News) -- A new U.S. ... to use the Internet for medical information, and whites are ... the findings released Thursday by the U.S. National Center for ... as likely as Hispanics to search for health information online. ...
... National Nanotechnology Initiative,s (NNI) released four reports that ... focusing on various issues in the nanotechnology environmental, ... series was a part of an ongoing strategy ... from industry, academia, and the Federal Government to ...
... the first time created a way of measuring how much force ... advance is expected to have significant implications for legal forensics. ... the force applied during a stabbing and come up with the ... work has been published in the International Journal of Legal ...
Cached Medicine News:Health News:BUSM/BMC researchers awarded $3.5 million grant from the NIDA 2Health News:Minority participants crucial to effective aging studies 2Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Women, Whites Most Likely to Seek Health Info Online: Survey 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 3
... offers the ease and comfort you've come to ... users in clinical trials agreed that the BD ... depth settings allow you to choose the best ... of lancets, the device also helps eliminate the ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
... The StaRRsed Compact is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: